Organigram reports Q4 revenue C$44.7M vs. C$36.7M last year

Reports Q4 adjusted EBITDA C$5.86M vs. C$58,000 last year. “Fiscal 2024 was a transformative year where our entire team delivered on multiple fronts,” said Beena Goldenberg, CEO. “We received significant funding from BAT when capital for the cannabis industry was scarce. We made smart, strategic investments, including into seed-based technology and automation, which is increasing efficiency. We have also expanded our international footprint through a $21 million investment in Sanity Group, a leading German cannabis company, as well as through several new supply agreements to provide products to patients in Australia and the UK. As we integrate recently-acquired Motif into the Organigram (OGI) ecosystem, we head into Fiscal 2025 as Canada’s #1 LP and we are very excited for the next phase of our growth plans focused on efficiency, consumer-centric innovation, and international expansion.”